Profile data is unavailable for this security.
About the company
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
- Revenue in USD (TTM)1.16bn
- Net income in USD34.55m
- Incorporated2004
- Employees4.20k
- LocationPenumbra IncOne Penumbra PlaceALAMEDA 94502United StatesUSA
- Phone+1 (510) 748-3200
- Fax+1 (302) 531-3150
- Websitehttps://www.penumbrainc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procept Biorobotics Corp | 199.84m | -100.06m | 5.11bn | 626.00 | -- | 20.42 | -- | 25.55 | -1.95 | -1.95 | 3.89 | 4.63 | 0.5026 | 1.83 | 3.86 | 319,238.00 | -25.16 | -- | -28.58 | -- | 57.39 | -- | -50.07 | -- | 5.07 | -- | 0.1758 | -- | 81.55 | -- | -21.51 | -- | -- | -- |
| Inspire Medical Systems Inc | 755.59m | 33.05m | 5.58bn | 1.01k | 171.11 | 8.01 | 146.81 | 7.38 | 1.09 | 1.09 | 25.15 | 23.25 | 1.05 | 2.46 | 9.37 | 747,372.90 | 4.60 | -11.27 | 5.12 | -12.60 | 84.77 | 84.47 | 4.37 | -13.57 | 6.94 | -- | 0.00 | -- | 53.19 | 65.32 | 52.87 | -- | 148.37 | -- |
| Stevanato Group SpA | 1.15bn | 120.12m | 5.94bn | 5.64k | 43.86 | 3.87 | 29.38 | 5.19 | 0.4473 | 0.4473 | 4.26 | 5.07 | 0.5284 | 2.75 | 2.66 | 203,340.60 | 5.54 | -- | 7.39 | -- | 29.20 | -- | 10.48 | -- | 1.21 | 48.53 | 0.2148 | -- | 10.34 | -- | 1.95 | -- | -- | -- |
| Lantheus Holdings Inc | 1.50bn | 427.61m | 6.07bn | 834.00 | 14.51 | 5.15 | 12.39 | 4.06 | 6.02 | 6.02 | 21.09 | 16.97 | 0.8383 | 8.28 | 5.09 | 1,794,723.00 | 23.95 | 6.69 | 32.76 | 7.73 | 64.78 | 57.56 | 28.57 | 9.02 | 1.56 | -- | 0.324 | 0.00 | 38.65 | 30.44 | 1,063.86 | 51.81 | 35.48 | -- |
| Merit Medical Systems Inc | 1.33bn | 120.04m | 6.12bn | 6.95k | 51.45 | 4.62 | 28.11 | 4.62 | 2.04 | 2.04 | 22.55 | 22.71 | 0.6334 | 2.29 | 7.41 | 190,772.80 | 5.73 | 2.45 | 6.32 | 2.77 | 46.83 | 44.50 | 9.05 | 3.91 | 3.82 | 31.88 | 0.3619 | 0.00 | 9.24 | 7.33 | 26.70 | 15.86 | -11.16 | -- |
| Glaukos Corp | 360.35m | -149.57m | 7.77bn | 907.00 | -- | 11.61 | -- | 21.55 | -2.96 | -2.96 | 7.06 | 12.13 | 0.3843 | 1.69 | 7.53 | 397,295.50 | -15.95 | -8.73 | -17.23 | -9.35 | 76.61 | 74.77 | -41.51 | -28.69 | 4.71 | -311.24 | 0.1591 | -- | 11.26 | 11.66 | -35.75 | -- | 14.44 | -- |
| Repligen Corp | 622.64m | -17.13m | 7.94bn | 1.78k | -- | 3.94 | 154.72 | 12.75 | -0.3079 | -0.3079 | 11.09 | 36.00 | 0.233 | 1.57 | 5.29 | 349,206.40 | -0.6411 | 4.38 | -0.7032 | 5.03 | 50.37 | 55.43 | -2.75 | 15.91 | 8.76 | -- | 0.2055 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
| Bruker Corp | 3.24bn | 304.90m | 8.52bn | 9.71k | 27.11 | 4.72 | 18.05 | 2.63 | 2.07 | 2.07 | 21.89 | 11.92 | 0.6527 | 1.51 | 5.73 | 333,913.70 | 6.12 | 8.38 | 8.14 | 11.40 | 49.31 | 49.85 | 9.38 | 11.39 | 0.7085 | 26.83 | 0.5549 | 9.81 | 17.14 | 9.36 | 44.03 | 18.91 | 16.79 | 4.56 |
| Teleflex Inc | 3.03bn | 238.01m | 8.85bn | 14.50k | 37.80 | 1.98 | 17.53 | 2.93 | 5.04 | 5.03 | 64.01 | 96.50 | 0.404 | 2.11 | 6.76 | 208,677.50 | 3.18 | 5.86 | 3.46 | 6.42 | 55.99 | 54.43 | 7.87 | 14.62 | 1.39 | 6.61 | 0.2818 | 15.84 | 6.57 | 3.97 | -1.47 | 12.73 | 2.51 | 0.00 |
| Masimo Corp | 2.04bn | 78.60m | 9.05bn | 3.80k | 116.32 | 6.18 | 52.25 | 4.43 | 1.45 | 1.45 | 37.72 | 27.35 | 0.6715 | 1.77 | 5.52 | 537,526.30 | 2.58 | 8.65 | 3.23 | 10.31 | 50.05 | 57.30 | 3.85 | 12.03 | 1.11 | 2.84 | 0.3456 | 0.00 | 0.6042 | 19.00 | -43.21 | -15.96 | 31.06 | -- |
| Bio Rad Laboratories Inc | 2.58bn | -778.69m | 9.16bn | 8.03k | -- | 1.22 | -- | 3.55 | -27.32 | -27.32 | 90.77 | 267.46 | 0.2294 | 1.49 | 5.61 | 321,321.20 | -6.92 | 9.08 | -7.26 | 9.60 | 54.43 | 55.55 | -30.18 | 41.97 | 4.52 | 0.2612 | 0.1383 | 0.00 | -4.67 | 3.13 | 82.43 | -- | 3.83 | -- |
| Henry Schein, Inc. | 12.50bn | 314.00m | 9.20bn | 25.00k | 30.21 | 2.64 | 15.54 | 0.7359 | 2.44 | 2.44 | 96.89 | 27.99 | 1.22 | 4.77 | 7.73 | 499,960.00 | 2.97 | 6.09 | 4.86 | 10.44 | 31.59 | 30.04 | 2.42 | 4.40 | 0.817 | 6.23 | 0.348 | 0.00 | -2.44 | 5.55 | -22.68 | -0.1456 | 21.27 | -- |
| Penumbra Inc | 1.16bn | 34.55m | 9.23bn | 4.20k | 279.56 | 8.35 | 151.56 | 7.93 | 0.8602 | 0.8602 | 29.71 | 28.78 | 0.7897 | 1.04 | 6.08 | 277,089.50 | 2.34 | 2.32 | 2.61 | 2.61 | 65.70 | 63.90 | 2.97 | 3.17 | 3.25 | -- | 0.0218 | 0.00 | 24.95 | 18.93 | 4,643.16 | 68.60 | 9.64 | -- |
| Solventum Corp | 8.22bn | 720.00m | 12.03bn | 22.01k | 16.72 | 3.77 | 9.51 | 1.46 | 4.16 | 4.16 | 47.45 | 18.48 | 0.5831 | 3.93 | 7.19 | 373,290.30 | 5.11 | -- | 6.03 | -- | 56.38 | -- | 8.76 | -- | 0.8268 | 5.02 | 0.7176 | -- | 0.8241 | -- | 0.2234 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Penumbra Inc's reporting currency: US Dollar USD
52.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 4.95m | 12.74% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 3.62m | 9.31% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 3.47m | 8.94% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 1.94m | 4.99% |
| Champlain Investment Partners LLCas of 30 Sep 2024 | 1.55m | 3.99% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.24m | 3.18% |
| William Blair Investment Management LLCas of 30 Sep 2024 | 990.19k | 2.55% |
| FIAM LLCas of 30 Sep 2024 | 948.97k | 2.44% |
| RTW Investments LPas of 30 Sep 2024 | 795.75k | 2.05% |
| ClearBridge Investments LLCas of 30 Sep 2024 | 710.05k | 1.83% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
